Leerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform May 5, 2016 3:25 PM Regeneron (REGN) Misses Q1 EPS by 1c; ReaffirmsMay 5, 2016 6:36 AM Regeneron Reports First Quarter 2016 Financial and Operating ResultsMay 5, 2016 6:30 AM Trading Radar for 5/5: Alibaba (BABA), GoPro (GPRO), Herbalife (HLF), Wynn Resorts (WYNN), Activision (ATVI) ReportMay 4, 2016 2:39 PM Sanofi sees 'strong strategic' fit with U.S. MedivationMay 4, 2016 10:39 AM